For information about any of these trials, you may contact the individuals who are listed with each trial or study below, or you may contact us at our general USC MS Comprehensive Care Center number (323-442-6870) or email address (mscare@usc.edu).
Please note that appointments to see our doctors for non-research related care may be made by calling the Weiner Neurology Clinic at 323-442-5710.
Rebif® New Formulation Tolerability Trial
Status:
CLOSED. Study Activities Ongoing
Sponsors:
Serono
Type of Study and Brief Description:
A randomized, two arm, open-label, 12 week phase IIIb study to evaluate the tolerability of Rebif® (IFN beta-1a) New Formulation and Betaseron® (IFN beta-1b) in subjects with relapsing remitting multiple sclerosis; followed by a single-arm, 24 week, Rebif®-only safety extension.
Background:
In this trial we hope the detect and measure an increased tolerability to the new formulation of Rebif®. The new formulation of Rebif® should be more tolerable than the presently approved medication. As a proven standard medication for RRMS, a more tolerable formula will lead to better patient compliance.
USC Principal Investigator:
Norman Kachuck, M.D.
Contact:
Jose Aparicio (323-442-6833 or joseapar@usc.edu)
Additional Information:
You can click here for a document that describes more about this trial.
Back to top
|
